Term ends no later than Dec 25, 2026 · Medium confidence
In force on USPTO's status record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Dec 25, 2012
Dec 25, 2026
This patent's term is its base term, 14 years from grant, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. No maintenance fees are payable on this kind of patent. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 14 years from grant | Granted Dec 25, 2012 | Dec 25, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Computed term end | The steps above, in order | no later than Dec 25, 2026 | Medium confidence |
This family
| US 9,011,386 | In force Oct 2032 | Oct 2032 |
| US D673,264 | this patent no later than Dec 2026 | no later than Dec 2026 |
| US 9,033,935 | In force Jul 2031 | Jul 2031 |
| US 9,033,936 | In force May 2031 | May 2031 |
| US 9,005,160 | In force Dec 2031 | Dec 2031 |
| US 8,986,245 | In force Jul 2031 | Jul 2031 |
| US 9,033,932 | In force Jul 2032 | Jul 2032 |
| US 9,011,375 | In force Feb 2032 | Feb 2032 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 19, 2010 Reel 23826, frame 403 | Kunze, Katja | SHL Group AB | Assignment of Assignor's Interest |
| Aug 1, 2016 Reel 39504, frame 486 | Novartis Pharma AG | Novartis AG | Assignment of Assignor's Interest |
| Aug 1, 2016 Reel 39515, frame 740 | SHL Group AB | Novartis Pharma AG | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center
No maintenance fees are payable on this kind of patent, so the record carries no fee events.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Dec 25, 2026. We will not guess the cap.